Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Terminated 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 1

Conditions

Blood Loss, Surgical 2Postoperative Hemorrhage 1Breast Neoplasms 1

Interventions

Cyclophosphamide 391Carboplatin 344Gemcitabine 332pembrolizumab 331Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 287Bevacizumab 253Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 190fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134Cetuximab 130fludarabine phosphate 129Bortezomib 129Lenalidomide 126Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Aprotinin × Clear all
NCT00306150 2014-12-17

Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy

Bayer

Phase 3 Terminated
57 enrolled

Blood Loss, Surgical, Postoperative Hemorrhage

NCT00306137 2014-12-09

Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer

Bayer

Phase 3 Terminated
104 enrolled

Blood Loss, Surgical

NCT00354900 2009-08-04

Phase I Study of Aprotinin in Advanced Breast Cancer

Dartmouth-Hitchcock Medical Center

Phase 1 Terminated
18 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡